Rapid virological response of telaprevir and boceprevir in a Brazilian cohort of HCV genotype I patients: a multicenter longitudinal study

被引:5
作者
Borba, Helena H. L. [1 ]
Wiens, Astrid [1 ]
Steimbach, Laiza M. [1 ]
Tonin, Fernanda S. [1 ]
Pedroso, Maria L. A. [2 ]
Ivantes, Claudia A. P. [3 ]
Fernandez-Llimos, Fernando [4 ]
Pontarolo, Roberto [1 ]
机构
[1] Univ Fed Parana, Hosp Clin, Dept Pharm, Pharmaceut Sci Postgrad Res Program, Curitiba, Parana, Brazil
[2] Univ Fed Parana, Hosp Clin, Gastroenterol Serv, Curitiba, Parana, Brazil
[3] Guidance & Counseling Ctr, Curitiba City Hall, Curitiba, Parana, Brazil
[4] Univ Lisbon, Res Inst Med, Fac Pharm, Dept Social Pharm, Lisbon, Portugal
关键词
hepatitis C; rapid virological response; protease inhibitors; telaprevir; boceprevir; multicenter; CHRONIC HEPATITIS-C; PROTEASE INHIBITORS; VIRUS; THERAPY; PREVALENCE; SAFETY;
D O I
10.2147/TCRM.S124663
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Chronic hepatitis C is a major public health issue, but there is a gap in the literature regarding the effectiveness and safety of direct-acting antiviral agents in the Brazilian population. The main aim of this study was to describe the effectiveness of boceprevir and telaprevir in patients treated at public health care institutions in Brazil. Materials and methods: A prospective longitudinal and multicenter study was conducted in five centers in the State of Parana between September 2014 and June 2016. Data regarding effectiveness and safety were collected from medical records of patients treated with boceprevir or telaprevir. The effectiveness outcome comprised the rapid virological response (RVR). Multivariate analysis was performed to verify the influence of independent variables (ie, age, gender, baseline viral load) on RVR achievement. Results: Data were collected from 117 patients with chronic hepatitis C virus (HCV) genotype 1 infection. Fifteen patients received treatment with boceprevir and 102 received telaprevir. The mean age was 51.6 years, 64.1% were male, 44.4% were infected with HCV subtype 1a, 62.4% had a high baseline viral load (>= 800,000 IU/mL) and 33% were cirrhotic. Furthermore, 79.5% of patients achieved RVR (26.7% in the boceprevir group and 87.3% in the telaprevir group). Multivariate analysis demonstrated that the type of protease inhibitor (boceprevir or telaprevir) and the baseline viral load had an influence on the RVR rate (odds ratio [OR] =0.011; 95% confidence interval [CI]: 0.001-0.119; P<0.001/OR = 13.004; 95% CI: 1.522-111.115; P=0.019, respectively). Conclusion: In this longitudinal multicenter cohort study conducted from the Brazilian perspective, differences were found in the RVR rates, favoring telaprevir over boceprevir for genotype 1 HCV-infected patients. In addition, the baseline viral load was associated with RVR achievement in both evaluated groups. As RVR is also reported in the literature as a predictor of the sustained virological response (SVR), further analyses of RVR as predictor of SVR outcomes should be further evaluated in Brazil.
引用
收藏
页码:59 / 64
页数:6
相关论文
共 33 条
  • [1] Disease burden of chronic hepatitis C in Brazil
    Abrao Ferreira, Paulo Roberto
    Brandao-Mello, Carlos Eduardo
    Estes, Chris
    Goncales Junior, Fernando Lopes
    Moraes Coelho, Henrique Sergio
    Razavi, Homie
    Cheinquer, Hugo
    Wolff, Fernando Herz
    Gomes Ferraz, Maria Lucia
    Pessoa, Mario Guimardes
    Mendes-Correa, Maria Cassia
    [J]. BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2015, 19 (04) : 363 - 368
  • [2] Protease inhibitors: Silver bullets for chronic hepatitis C infection?
    Alkhouri, Naim
    Zein, Nizar N.
    [J]. CLEVELAND CLINIC JOURNAL OF MEDICINE, 2012, 79 (03) : 213 - 222
  • [3] ALMEIDA Paulo R L, 2015, Arq. Gastroenterol., V52, P14, DOI 10.1590/S0004-28032015000100004
  • [4] Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen - The ANRS CO20-CUPIC study
    Bailly, Francois
    Virlogeux, Victor
    Dufour, Cecilie
    Pradat, Pierre
    Hezode, Christophe
    Larrey, Dominique
    Alric, Laurent
    Samuel, Didier
    Bourliere, Marc
    Metivier, Sophie
    Zarski, Jean-Pierre
    Fontaine, Helene
    Loustaud-Ratti, Veronique
    Serfaty, Lawrence
    Bronowicki, Jean-Pierre
    Carrat, Fabrice
    Zoulim, Fabien
    [J]. CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2015, 39 (04) : 443 - 450
  • [5] BEDOSSA P, 1994, HEPATOLOGY, V20, P15
  • [6] Early Virologic Responses and Hematologic Safety of Direct-Acting Antiviral Therapies in Veterans With Chronic Hepatitis C
    Belperio, Pamela S.
    Hwang, Elizabeth W.
    Thomas, I. Chun
    Mole, Larry A.
    Cheung, Ramsey C.
    Backus, Lisa I.
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2013, 11 (08) : 1021 - 1027
  • [7] Black N, 1996, BRIT MED J, V312, P1215
  • [8] Brazilian Ministry of Health, 2012, IN PROT BOC TEL TRAT
  • [9] Brazilian Ministry of Health, 2015, B EP HEP VIR
  • [10] Brazilian Ministry of Health, 2015, SIM SOF DACL TRAT HE